SCHEMBL2851294

SCHEMBL2851294

Nc1nc2ccc(Oc3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)nc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.56
BRAF P15056 2/20 0.56
PDGFRB P09619 2/20 0.56
KIT P10721 2/20 0.56
FLT1 P17948 2/20 0.56
FGFR1 P11362 1/20 0.56
PDGFRA P16234 1/20 0.56
FGFR3 P22607 1/20 0.56
TEK Q02763 1/20 0.56
GAA P10253 2/20 0.54
MAPT P10636 4/20 0.53
MAPK1 P28482 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
PTGS1 P23219 2/20 0.53
RAB9A P51151 2/20 0.49
KCNK3 O14649 1/20 0.49
RET P07949 1/20 0.49
FLT4 P35916 1/20 0.49
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862024 0.87 BRAF (0.56) KDRBRAF
SCHEMBL2858206 0.86 KDR (0.51) KDRBRAFPDGFRBKITPDGFRA
SCHEMBL2855717 0.85 KDR (0.54) KDRBRAFPDGFRBKITFLT1
SCHEMBL2857661 0.85 KDR (0.51) KDRBRAFPDGFRBKITFLT1
SCHEMBL2853887 0.85 KDR (0.64) KDRBRAFPDGFRBKITFLT1
SCHEMBL2196842 0.81 ALDH1A1 (0.55) KDRTEKGAAMAPTMAPK1
SCHEMBL2853872 0.81 KDR (0.47) KDRBRAFPDGFRBKITFLT1
SCHEMBL2861313 0.81 KDR (0.49) KDRPDGFRBKITFLT1MAPT
SCHEMBL1279505 0.81 LCK (0.60) KDRPDGFRBTEKMAPTMAPK1
SCHEMBL2859339 0.81 GAA (0.71) KDRBRAFPDGFRBKITFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 KDR 983/4885BRAF 1/4885PDGFRB 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.